Loading stock data…
SEPN
$23.61-0.15 (-0.63%)
Market ClosedLast close May 1
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Septerna, Inc. in the Healthcare sector is trading at $23.61. The stock is currently 28% below its 52-week high of $32.63, remaining 7.6% above its 200-day moving average. Technical signals show neutral RSI of 51 and bearish MACD signal, explaining why SEPN maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$23.61
Potential Upside
5%
Whystock Fair Value$24.79
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R P...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-12.80%
Volume
Today's trading volume
189,704
Recent News
Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates
Septerna, Inc. (SEPN) delivered earnings and revenue surprises of -5.50% and +17.98%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Does SEP-631’s Phase 1 Proof-of-Mechanism and 2026 Trial Plan Reshape Septerna’s Mast Cell Strategy (SEPN)?
Septerna has reported positive past Phase 1 results for SEP-631, an oral negative allosteric modulator of MRGPRX2, showing robust target engagement, functional pathway blockade, and tolerability comparable to placebo, and it plans to start a Phase 2b chronic spontaneous urticaria trial in the second half of 2026 after completing long-term toxicology studies. By pairing clinical proof-of-mechanism with an oral, once-daily profile in a mast cell-driven condition, SEP-631 positions Septerna to...
Assessing Septerna (SEPN) Valuation After Recent Share Price Pullback And One Year 40.63% Return
Septerna (SEPN) is back on investor radars after recent trading pressure, with the stock down about 9.6% over the past week and modestly weaker over the past month, despite stronger performance over the past three months. See our latest analysis for Septerna. Stepping back from the latest pullback, Septerna’s share price return over the past 90 days is positive, while the year to date share price return is weaker and contrasts with a 1 year total shareholder return of 40.63%. This hints at...
Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls
Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls
Why Septerna (SEPN) Is Up 28.5% After Posting a Surprise Profit and Analyst Upgrades
Septerna, Inc. recently reported third-quarter 2025 earnings, revealing a surge in sales to US$21.5 million and a shift from a net loss to net income compared to the same period last year. Following this dramatic improvement in financial performance, several research analysts upgraded their outlooks, underscoring renewed confidence in Septerna's business trajectory. With earnings turning positive and notable analyst upgrades, we'll explore how Septerna's investment narrative is being...